- Molecular NameEnoxaparin
- SynonymEnoxaparin; LMWH; Low Molecular Weight Heparin
- Weight1134.93
- Drugbank_IDDB01225
- ACS_NO74011-58-8
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pkaN/A
- LogD (pH=7, predicted)N/A
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationSubcutaneous (SC) Injection and intervenous (IV) per package insert
- PharmacologyA drug used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection (by a health care provider or the patient). Its use is evolving in acute coronary syndromes (ACS).
- Absorption_valueN/A
- Absorption (description)Enoxaparin is poorly absorbed after oral administration.Enoxaparin is rapidly and completely absorbed after subcutaneous injection with a peak plasma activity reached in 1 to 5 h.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding80.0
- Volume of distribution (VD)0.12 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is metabolised in the liver by desulfation and depolymerisation.
- Half life3.8 h
- ExcretionIt is excreted via the kidneys and is found unchanged and as its metabolites in urine.
- Urinary ExcretionN/A
- Clerance0.3 ml/min/kg
- ToxicityLarge oral doses should not lead to any serious effects. Accidental overdosing, by parenteral administration, may lead to haemorrhagic problems with severe bleeding. Risk of bleeding increases with plasma concentrations of antifactor XA > 0.4 units/mL.
- LD50 (rat)N/A
- LD50 (mouse)N/A